Friday, July 10, 2026

pharma · No medical condition. · Breast cancer

George Institute for

George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER

Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Clinical program

TRACK_001

Phase 3 · small molecule · Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

TRACK_001 for Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease. is a Phase 3 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

← All The George Institute projects Phase 3 small molecule active

Internal code TRACK_001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
The George Institute
Phase
Phase 3
Modality
small_molecule
Indication
Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.
Status
active
Trials
1